Compare Repligen Corporation Common Stock (RGEN) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Wayfair Inc — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Wayfair Inc trades at $104.22 (market cap $14.35B). The key difference: Wayfair Inc is the larger of the two by market cap, and Wayfair Inc is more actively traded (2,196,186 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| RGEN | W | |
|---|---|---|
Market Cap | $11.31B | $14.35B |
Volume | 1,216,919 | 2,196,186 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $119.05 |
52-Week Low | $102.87 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $11.20B | $16.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Wayfair (W) trades at $107.99, up 1.74% today, with bullish technical signals from moving averages and a consensus price target of $114.13. The company shows strong revenue growth with $12.46B in 2025, though negative net income margins persist. Recent developments include the launch of 'Wayfair Delivers' brand platform and upcoming Q3 2026 earnings release on November 4, 2026.
The outlook remains cautiously optimistic with analyst support (54% buy ratings) and technical momentum, but profitability challenges and high debt-to-asset ratio of 95.11% present significant risks. The stock's current position near resistance at $108 suggests potential for breakout if Q3 earnings beat expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
